Trk-750
Chemotherapy-induced Peripheral Neuropathy
Toray Industries, IncSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
30 Active assets in the Chemotherapy-induced Peripheral Neuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin University of Rochester | Phase 4 | BB |
Omeprazole Aya Mohamed Sadek Elsaid | Phase 3 | BB |
LIDOCAINE Hospital Ambroise Paré Paris | Phase 2 | BB |
Mecobalamin Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 2/3 | B |
Vitamin B6 Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 2/3 | B |
View all 46 →
Same molecule, other indications
Trk-750 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →